Epigenetic Drugs: Team Players in Combo Therapies

Sharma S. et al., “Epigenetics in Cancer,” Carcinogenesis , 31(1), 27–36 (January 1, 2010), https://doi.org/10.1093/carcin/bgp220.

Hermann F. , “Clinical Development of 4SC-202, A Combined Epigenetic Inhibitor of HDAC Class I and LSD1, to Overcome Anti-PD-1 Refractoriness and Increase Efficacy of Checkpoint Inhibition,” J. Clin. Oncol. , 35(15_suppl), doi: 10.1200/JCO.2017.35.15_suppl.e14096.

Aldana-Masangkay G.I. and Sakamoto K.M. , “The Role of HDAC6 in Cancer,” J. Biomed. Biotechnol. (published online November 7, 2010), doi:10.1155/2011/875824.

Shuttleworth S.J. , “Abstract 3996: KA2237 and KA2507: Novel, Oral Cancer Immunotherapeutics Targeting PI3K-p110β/p110δ and HDAC6 with Single-Agent and Combination Activity,” Proceedings: AACR 107th Annual Meeting 2016, (April 16–20, 2016, New Orleans, LA, published July 2016), doi:10.1158/1538-7445.AM2016-3996.

Wang Z. et al., “HDAC6 Promotes Cell Proliferation and Confers Resistance to Temozolomide in Glioblastoma,” Cancer Lett. , 379(1), 134–142 (August 28, 2016).

Zhang L. et al., “Tubastatin A/ACY-1215 Improves Cognition in Alzheimer’s Disease Transgenic Mice,” J. Alz. Dis. , 41(4), 1193–1205 (2014).